{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:11:55Z","timestamp":1762809115296,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Treatment with exogenous GLP-2 has been shown to accelerate the growth of intestinal adenomas and adenocarcinomas in experimental models of colonic neoplasia, however, the role of endogenous GLP-2 in tumor promotion is less well known. Mice with a global deletion of the glucagon receptor (Gcgr<jats:sup>-\/-<\/jats:sup>) display an increase in circulating GLP-1 and GLP-2. Due to the intestinotrophic nature of GLP-2, we hypothesized that Gcgr<jats:sup>-\/-<\/jats:sup> mice would be more susceptible to colonic dysplasia in a model of inflammation-induced colonic carcinogenesis. Female Gcgr<jats:sup>-\/-<\/jats:sup> mice were first characterized for GLP-2 secretion and in a subsequent study they were given a single injection with the carcinogen azoxymethane (7.5 mg\/kg) and treated with dextran sodium sulfate (DSS) (3%) for six days (n=19 and 9). A cohort of animals (n=4) received a colonoscopy 12 days following DSS treatment and all animals were sacrificed after six weeks. Disruption of glucagon receptor signaling led to increased GLP-2 secretion (p&amp;lt;0.0001) and an increased concentration of GLP-2 in the pancreas of Gcgr<jats:sup>-\/-<\/jats:sup> mice, coinciding with an increase in small intestinal (p&amp;lt;0.0001) and colonic (p&amp;lt;0.05) weight. Increased villus height was recorded in the duodenum (p&amp;lt;0.001) and crypt depth was increased in the duodenum and jejunum (p&amp;lt;0.05 and p&amp;lt;0.05). Disruption of glucagon receptor signaling did not affect body weight during AOM\/DSS treatment, neither did it affect the inflammatory score assessed during colonoscopy or the number of large and small adenomas present at the end of the study period. In conclusion, despite the increased endogenous GLP-2 secretion Gcgr<jats:sup>-\/-<\/jats:sup> mice were not more susceptible to AOM\/DSS-induced tumors.<\/jats:p>","DOI":"10.3389\/fendo.2021.695145","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:19:52Z","timestamp":1621837192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM\/DSS-Induced Tumors"],"prefix":"10.3389","volume":"12","author":[{"given":"Jenna Elizabeth","family":"Hunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannelouise","family":"Kissow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of Intestinal Epithelial Proliferation by Glucagon-Like Peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0196-9781(99)00176-X","article-title":"Structure, Measurement, and Secretion of Human Glucagon-Like Peptide-2","volume":"21","author":"Hartmann","year":"2000","journal-title":"Peptides"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.8.3242","article-title":"Proglucagon is Processed to Glucagon by Prohormone Convertase PC2 in Alpha TC1-6 Cells","volume":"91","author":"Rouille","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-Like Peptide 2 Improves Nutrient Absorption and Nutritional Status in Short-Bowel Patients With No Colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005572832571","article-title":"Intestinal Growth Adaptation and Glucagon-Like Peptide 2 in Rats With Ileal\u2013Jejunal Transposition or Small Bowel Resection","volume":"46","author":"Thulesen","year":"2001","journal-title":"Dig Dis Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1210\/en.2004-1119","article-title":"Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets","volume":"146","author":"Burrin","year":"2005","journal-title":"Endocrinology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1997.272.6.E1050","article-title":"Intestinal Function in Mice With Small Bowel Growth Induced by Glucagon-Like Peptide-2","volume":"272","author":"Brubaker","year":"1997","journal-title":"Am J Physiol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9610(01)00635-3","article-title":"The Effect of Glucagon-Like Peptide 2 on Intestinal Permeability and Bacterial Translocation in Acute Necrotizing Pancreatitis","volume":"181","author":"Kouris","year":"2001","journal-title":"Am J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.005","article-title":"Glp-2 Receptor Localizes to Enteric Neurons and Endocrine Cells Expressing Vasoactive Peptides and Mediates Increased Blood Flow","volume":"130","author":"Guan","year":"2006","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00588.2005","article-title":"Glucagon-Like Peptide-2 Acutely Increases Proximal Small Intestinal Blood Flow in TPN-Fed Neonatal Piglets","volume":"290","author":"Stephens","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.02.033","article-title":"Mucosal Adaptation to Enteral Nutrients is Dependent on the Physiologic Actions of Glucagon-Like Peptide-2 in Mice","volume":"128","author":"Shin","year":"2005","journal-title":"Gastroenterology"},{"year":"2019","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0295","article-title":"Carcinogenic Effects of Exogenous and Endogenous Glucagon-Like Peptide-2 in Azoxymethane-Treated Mice","volume":"150","author":"Iakoubov","year":"2009","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035212","article-title":"Glucagon-Like Peptide 2 (GLP-2) Accelerates the Growth of Colonic Neoplasms in Mice","volume":"53","author":"Thulesen","year":"2004","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0029","article-title":"Glucagon-Like Peptide-2 Does Not Modify the Growth or Survival of Murine or Human Intestinal Tumor Cells","volume":"68","author":"Koehler","year":"2008","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0237106100","article-title":"Lower Blood Glucose, Hyperglucagonemia, and Pancreatic \u03b1 Cell Hyperplasia in Glucagon Receptor Knockout Mice","volume":"100","author":"Gelling","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00102.2010","article-title":"Glucagon Receptor Antagonist-Mediated Improvements in Glycemic Control are Dependent on Functional Pancreatic GLP-1 Receptor","volume":"299","author":"Gu","year":"2010","journal-title":"AJP Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.157685","article-title":"Long-Term Inhibition of the Glucagon Receptor With a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, With Reversible \u03b1-Cell Hyperplasia and Hyperglucagonemia","volume":"331","author":"Gu","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43615","article-title":"Dual Elimination of the Glucagon and GLP-1 Receptors in Mice Reveals Plasticity in the Incretin Axis","volume":"121","author":"Ali","year":"2011","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin Secretion Depends on Intra-Islet Glucagon Signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1152\/ajpendo.00198.2017","article-title":"Disruption of Glucagon Receptor Signaling Causes Hyperaminoacidemia Exposing a Possible Liver - Alpha-Cell Axis","volume":"314","author":"Galsgaard","year":"2017","journal-title":"Am J Physiol - Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0481-3","article-title":"Glucagon Receptor Knockout Mice Are Resistant to Diet-Induced Obesity and Streptozotocin-Mediated Beta Cell Loss and Hyperglycaemia","volume":"50","author":"Conarello","year":"2007","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32241-X","article-title":"Proglucagon Processing in Porcine and Human Pancreas","volume":"269","author":"Holst","year":"1994","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e59236","DOI":"10.3791\/59236","article-title":"Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation Using a Mouse Model of Chemotherapy-Induced Mucositis","volume":"147","author":"Billeschou","year":"2019","journal-title":"J Vis Exp"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-016-1872-2","article-title":"The Intestinal Distribution Pattern of Appetite and Glucose Regulatory Peptides in Mice, Rats and Pigs","volume":"9","author":"Albrechtsen","year":"2016","journal-title":"BMC Res Notes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.446","article-title":"High Resolution Colonoscopy in Live Mice","volume":"1","author":"Becker","year":"2007","journal-title":"Nat Protoc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.061440","article-title":"Teduglutide (ALX-0600), a Dipeptidyl Peptidase IV Resistant Glucagon-Like Peptide 2 Analogue, Improves Intestinal Function in Short Bowel Syndrome Patients","volume":"54","author":"Jeppesen","year":"2005","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3168\/jds.2010-3540","article-title":"Glucagon-Like Peptide-2 (GLP-2) Increases Small Intestinal Blood Flow and Mucosal Growth in Ruminating Calves","volume":"94","author":"Taylor-Edwards","year":"2011","journal-title":"J Dairy Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/1477-3163.49014","article-title":"Colorectal Carcinogenesis: Review of Human and Experimental Animal Studies","volume":"8","author":"Takuji","year":"2009","journal-title":"J Carcinog"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.695145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:19:54Z","timestamp":1621837194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.695145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":29,"alternative-id":["10.3389\/fendo.2021.695145"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.695145","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"article-number":"695145"}}